Treated Cases of Retinopathy of Prematurity in Germany: 10-Year Data from the Retina.net Retinopathy of Prematurity Registry
Standard
Treated Cases of Retinopathy of Prematurity in Germany: 10-Year Data from the Retina.net Retinopathy of Prematurity Registry. / Pfeil, Johanna M; Barth, Teresa; Lagrèze, Wolf A; Lorenz, Birgit; Hufendiek, Karsten; Liegl, Raffael; Breuss, Helge; Bemme, Sebastian; Aisenbrey, Sabine; Glitz, Barbara; Süsskind, Daniela; Gabel-Pfisterer, Ameli; Skevas, Christos; Krohne, Tim U; Kakkassery, Vinodh; Bründer, Marie-Christine; Engelmann, Katrin; Guthoff, Rainer; Walter, Peter; Choritz, Lars; Stahl, Andreas; Retina.net ROP Registry.
in: OPHTHALMOL RETINA, Jahrgang 8, Nr. 6, 06.2024, S. 579-589.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Treated Cases of Retinopathy of Prematurity in Germany: 10-Year Data from the Retina.net Retinopathy of Prematurity Registry
AU - Pfeil, Johanna M
AU - Barth, Teresa
AU - Lagrèze, Wolf A
AU - Lorenz, Birgit
AU - Hufendiek, Karsten
AU - Liegl, Raffael
AU - Breuss, Helge
AU - Bemme, Sebastian
AU - Aisenbrey, Sabine
AU - Glitz, Barbara
AU - Süsskind, Daniela
AU - Gabel-Pfisterer, Ameli
AU - Skevas, Christos
AU - Krohne, Tim U
AU - Kakkassery, Vinodh
AU - Bründer, Marie-Christine
AU - Engelmann, Katrin
AU - Guthoff, Rainer
AU - Walter, Peter
AU - Choritz, Lars
AU - Stahl, Andreas
AU - Retina.net ROP Registry
AU - Hagenau, Felix
AU - Spitzer, Martin
N1 - Copyright © 2023. Published by Elsevier Inc.
PY - 2024/6
Y1 - 2024/6
N2 - PURPOSE: To analyze changes in demographic parameters and retreatment patterns over a 10-year period in a clinical routine setting of infants with retinopathy of prematurity (ROP) requiring treatment documented in the German Retina.net ROP registry.DESIGN: Multicenter, noninterventional, observational registry study recruiting patients treated for ROP.SUBJECTS: A total of 692 eyes of 353 infants treated for ROP were documented in the Retina.net ROP registry over a 10-year period between 2011 and 2020. These cases cover about 15% of all infants treated for ROP in Germany.METHODS: The Retina.net ROP registry was established in 2012 to jointly collect information on infants treated for ROP. The database collects information on demographic parameters (gestational age [GA], birth weight, neonatal comorbidities) as well as treatment parameters (type of treatment, weight and age at treatment, and stage of ROP). A total of 19 centers contributed to the analysis. This is the 10-year analysis of data from 2011 to 2020, in which we focus on changes over time regarding the respective parameters.MAIN OUTCOME MEASURES: Changes over time in demographic parameters and treatment patterns for ROP in Germany.RESULTS: The overall incidence of treatment requiring ROP was 3.5% of all infants screened for ROP at participating centers. Gestational age, weight at birth, and weight at treatment remained stable over the 10-year period, whereas postmenstrual and postnatal age at treatment increased moderately but statistically significantly over the years. The most prevalent ROP severity stage at treatment was stage 3+ in zone II (76.6% of all treated eyes). Treatment patterns changed considerably from predominantly laser treatments in 2011 (75% of all treated eyes) to predominantly ranibizumab treatments in 2020 (60.9% of all treated eyes). The overall retreatment rate was 15.6%. Retreatment rates differed between initial treatment modalities (14.1% after laser coagulation, 12% after bevacizumab and 24.5% after ranibizumab). Treatment-associated systemic or ophthalmic complications were rare.CONCLUSIONS: This data analysis represents one of the largest documented cohorts of infants treated for ROP. The data on demographic parameters and treatment patterns provide useful information for further improvement of ROP management.FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
AB - PURPOSE: To analyze changes in demographic parameters and retreatment patterns over a 10-year period in a clinical routine setting of infants with retinopathy of prematurity (ROP) requiring treatment documented in the German Retina.net ROP registry.DESIGN: Multicenter, noninterventional, observational registry study recruiting patients treated for ROP.SUBJECTS: A total of 692 eyes of 353 infants treated for ROP were documented in the Retina.net ROP registry over a 10-year period between 2011 and 2020. These cases cover about 15% of all infants treated for ROP in Germany.METHODS: The Retina.net ROP registry was established in 2012 to jointly collect information on infants treated for ROP. The database collects information on demographic parameters (gestational age [GA], birth weight, neonatal comorbidities) as well as treatment parameters (type of treatment, weight and age at treatment, and stage of ROP). A total of 19 centers contributed to the analysis. This is the 10-year analysis of data from 2011 to 2020, in which we focus on changes over time regarding the respective parameters.MAIN OUTCOME MEASURES: Changes over time in demographic parameters and treatment patterns for ROP in Germany.RESULTS: The overall incidence of treatment requiring ROP was 3.5% of all infants screened for ROP at participating centers. Gestational age, weight at birth, and weight at treatment remained stable over the 10-year period, whereas postmenstrual and postnatal age at treatment increased moderately but statistically significantly over the years. The most prevalent ROP severity stage at treatment was stage 3+ in zone II (76.6% of all treated eyes). Treatment patterns changed considerably from predominantly laser treatments in 2011 (75% of all treated eyes) to predominantly ranibizumab treatments in 2020 (60.9% of all treated eyes). The overall retreatment rate was 15.6%. Retreatment rates differed between initial treatment modalities (14.1% after laser coagulation, 12% after bevacizumab and 24.5% after ranibizumab). Treatment-associated systemic or ophthalmic complications were rare.CONCLUSIONS: This data analysis represents one of the largest documented cohorts of infants treated for ROP. The data on demographic parameters and treatment patterns provide useful information for further improvement of ROP management.FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
KW - Angiogenesis Inhibitors/administration & dosage
KW - Female
KW - Follow-Up Studies
KW - Germany/epidemiology
KW - Gestational Age
KW - Humans
KW - Incidence
KW - Infant
KW - Infant, Newborn
KW - Intravitreal Injections
KW - Laser Coagulation/methods
KW - Male
KW - Registries
KW - Retinopathy of Prematurity/epidemiology
KW - Retrospective Studies
U2 - 10.1016/j.oret.2023.12.002
DO - 10.1016/j.oret.2023.12.002
M3 - SCORING: Journal article
C2 - 38104929
VL - 8
SP - 579
EP - 589
JO - OPHTHALMOL RETINA
JF - OPHTHALMOL RETINA
SN - 2468-6530
IS - 6
ER -